Generic Drug Patent Cases Fell By One-Third In 2016: Report

Law360, New York (April 27, 2017, 6:59 PM EDT) -- The number of patent suits over generic drugs filed in 2016 dropped by 32.5 percent over the previous year, according to a report released on Thursday by Lex Machina, a decline that an attorney says may be due to the rise of inter partes reviews and other factors.

The legal analytics firm's third annual report on litigation involving Abbreviated New Drug Applications under the Hatch-Waxman Act found that 316 ANDA suits were filed in 2016, down from 468 in 2015 and 433 in 2014.

Still, the number of suits filed last year was higher than the average of 269 ANDA cases...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!